Antipsychotic Medication and Diabetes Mellitusrs
J Clin Psychiatry 2005;66(3):395[letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Spoelstra and colleagues1
assert that antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus and speculate from their pharmacoepidemiologic study that this worsening is probably due to β-cell toxicity. While there is general agreement that exposure to antipsychotic medications (and second-generation agents in particular) may be associated with an increased risk of diabetes mellitus,2
there are several problems regarding the authors’ interpretation of the data. First, a comparison group of those not taking antipsychotics is probably not comparable to a group taking these medications.